MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 (MOR) Upgraded at Zacks Investment Research

Share on StockTwits

MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 (NYSEARCA:MOR) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Saturday. The firm presently has a $27.00 price objective on the stock. Zacks Investment Research‘s price target would indicate a potential upside of 12.45% from the company’s previous close.

According to Zacks, “MorphoSys AG is a biopharmaceutical company. It develops treatment for cancer, inflammations and autoimmune diseases. The company’s proprietary portfolio consists of MOR208, MOR202, MOR103, MOR106 and MOR107. Its partnered programs lighthouse project includes Tremfya(R) and Gantenerumab. MorphoSys AG is based in Planegg, Germany. “

Separately, Deutsche Bank upgraded MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 from a “hold” rating to a “buy” rating in a report on Monday, December 10th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 has an average rating of “Buy” and a consensus target price of $34.25.

NYSEARCA MOR opened at $24.01 on Friday. MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 has a 1 year low of $21.75 and a 1 year high of $35.90.

Featured Story: How to find the components of the quick ratio

Get a free copy of the Zacks research report on MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 (MOR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 (NYSEARCA:MOR)

Receive News & Ratings for MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500  Upgraded at Zacks Investment Research
MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 Upgraded at Zacks Investment Research
IHI CORP/ADR  Downgraded by Zacks Investment Research
IHI CORP/ADR Downgraded by Zacks Investment Research
Eyepoint Pharmaceuticals Inc Expected to Post Q3 2019 Earnings of  Per Share
Eyepoint Pharmaceuticals Inc Expected to Post Q3 2019 Earnings of Per Share
Cott Corp  to Post Q1 2019 Earnings of  Per Share, Jefferies Financial Group Forecasts
Cott Corp to Post Q1 2019 Earnings of Per Share, Jefferies Financial Group Forecasts
PennyMac Financial Services Inc to Post Q3 2019 Earnings of $0.72 Per Share, Piper Jaffray Companies Forecasts
PennyMac Financial Services Inc to Post Q3 2019 Earnings of $0.72 Per Share, Piper Jaffray Companies Forecasts
Rathbone Brothers plc  Receives Average Rating of “Buy” from Brokerages
Rathbone Brothers plc Receives Average Rating of “Buy” from Brokerages


Leave a Reply

© 2006-2019 Ticker Report